Clinical Trials on Gastrointestinal Carcinoma

Total 44147 results

University of Arizona

Terminated

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

Basal Cell Carcinomas

United States
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tang-Du Hospital

Recruiting

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Chemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | Neoadjuvent

China
Yongshun Chen

Recruiting

Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237）

Esophageal Squamous Cell Carcinoma

China
Renmin Hospital of Wuhan University

Recruiting

A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Shanghai Chest Hospital; Sixth Affiliated Hospital,... and other collaborators

Not yet recruiting

Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy

Esophageal Squamous Cell Carcinoma

China
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
Mian XI

Recruiting

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma | Neoplasm, Esophageal

China
Fudan University

Not yet recruiting

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin

Esophageal Squamous Cell Carcinoma | Positive Circumferential Resection Margin
BeiGene

Completed

AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of, Spain, China, Thailand, Taiwan, France
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (OASIS)

Gastric Adenocarcinoma | Esophageal Squamous Cell Carcinoma
Peking University

Unknown

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Esophageal Squamous Cell Carcinoma

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

China
Thomas Jefferson University

Recruiting

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Lung Carcinoma | Esophageal Carcinoma

United States
The First People's Hospital of Changzhou

Not yet recruiting

CIK in Treating Patients With Esophageal Cancer

Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Esophageal Carcinoma | Esophagogastric Junction Carcinoma

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group Limited

Completed

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Esophageal Squamous Cell Carcinoma

China
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Terminated

A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Esophageal Neoplasms

Japan
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
Yonsei University

Active, not recruiting

Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment

Korea, Republic of
Guo Xufeng

Recruiting

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Adjuvant Therapy | Neoadjuvant Chemoimmunotherapy

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Fuzhou General Hospital

Recruiting

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Immunotherapy Esophagus Cancer

China
Fudan University

Recruiting

ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) (HYPERION)

Esophageal Squamous Cell Carcinoma

China
Daping Hospital and the Research Institute of Surgery...

Active, not recruiting

PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy

Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.
Fortrea

Completed

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (ORIENT-15)

Esophageal Squamous Cell Carcinoma

France, Spain, Belgium, Australia, United States, China, Hungary
UNC Lineberger Comprehensive Cancer Center

Completed

HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi

Esophageal Squamous Cell Carcinoma

Malawi
Fudan University

Completed

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

China
Sichuan Cancer Hospital and Research Institute

Unknown

Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction

Esophageal Squamous Cell Carcinoma

China
Xijing Hospital of Digestive Diseases
Shanghai Zhongshan Hospital; Tongji Hospital; Peking University Cancer Hospital... and other collaborators

Completed

Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell Carcinoma

Esophageal Superficial Mucosal Lesion

China
Shanghai Chest Hospital
First Affiliated Hospital of Suzhou Medical College

Unknown

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Yonsei University

Completed

A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Esophageal Squamous Cell Carcinoma

Korea, Republic of
HiberCell, Inc.

Completed

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

Recurrent Colorectal Carcinoma | Progressive Colorectal Carcinoma

Philippines
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma | Unresectable Locally Advanced Esophageal Cancer

China
Shandong University

Completed

Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell Carcinoma

Artificial Intelligence | Optical Enhancement Endoscopy | Magnifying Endoscopy

China
Millennium Pharmaceuticals, Inc.

Terminated

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Recurrent Gastric Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Advanced Gastrointestinal Carcinoma | Recurrent Gastrointestinal Carcinoma

Taiwan, Korea, Republic of, Japan
Northwestern University
National Cancer Institute (NCI)

Completed

Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction

Quality of Life | Gastric Cancer | Colorectal Cancer | Small Intestine Cancer | Gastrointestinal Stromal Tumor | Constipation, Impaction, and Bowel Obstruction | Gastrointestinal Carcinoid Tumor

United States
Sun Yat-sen University

Recruiting

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (EC-CRT-006)

Esophagus Cancer

China
Centre Hospitalier Universitaire de Besancon

Completed

Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma (Epitopes-HPV02)

Anal Canal Carcinoma

France
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

Gastric Carcinoma | Unresectable Pancreatic Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Esophageal Carcinoma

United States
Stanford University

Withdrawn

School Response to Families Who Have Children With Cancer

Adenocarcinoma | Squamous Cell Carcinoma | Carcinomas

United States
Jianhua Fu

Unknown

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Resectable Esophageal Cancer | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China
Maria Sklodowska-Curie National Research Institute...
Centre of Postgraduate Medical Education

Completed

The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck | Esophageal Squamous Cell Carcinoma

Poland
Jules Bordet Institute
Innate Pharma

Withdrawn

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (ARTEMIS-Eso)

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus

Belgium
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
Dallas VA Medical Center

Recruiting

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma | Esophagus Adenocarcinoma | Esophagus Squamous Cell Carcinoma

United States

Clinical Trials on Gastrointestinal Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations